Our findings, together with others, thus highlight a broad role of hijacking a histone acetyltransferase (HAT) activity for oncogenesis, which justifies development of selective HAT inhibitors for anti-cancer therapy. The gene discussed is TMPRSS11D; the disease is cancer.